Articles From: Synchrony Financial Reports Third Quarter Net Earnings of $548 Million or $0.70 Per Diluted Share to Syngenta Expects Chinese Approval for Viptera Corn In Near Future


Synchrony Financial (NYSE:SYF) today announced third quarter 2014 net earnings of $548 million, or $0.70 per diluted share.
Sign-up for Synchrony Financial Reports Third Quarter Net Earnings of $548 Million or $0.70 Per Diluted Share investment picks
Synchrony Financial (NYSE:SYF) plans to report its third quarter 2014 results before the market opens on Friday, October 17, 2014.
Sign-up for Synchrony Financial to Announce Third Quarter 2014 Financial Results October 17, 2014 investment picks
Synchrony Financial (NYSE:SYF) President and Chief Executive Officer Margaret M.
Sign-up for Synchrony Financial to Participate in the Goldman Sachs US Financial Services Conference investment picks
Synchrony Financial (NYSE: SYF ) President and Chief Executive Officer Margaret M.
Sign-up for Synchrony Financial to Present at the Bank of America Merrill Lynch Banking & Financial Services Conference investment picks
Synchrony Financial (NYSE:SYF), one of the nation’s premier consumer financial services companies, has earned six Platinum and Silver awards in the 2014 Summit Marketing Effectiveness Award (Summit MEA) competition for multiple marketing communication initiatives for its Optimizer +plus branded, FDIC-insured savings products through Synchrony Bank.
Sign-up for Synchrony Financial’s Optimizer+plus Takes Top Advertising Effectiveness Awards investment picks
Synchrony Financial (NYSE: SYF ), a premier consumer financial services company with 80 years of retail heritage, and its People with Disabilities Network (PDN) hosted an employee and community partner event on November 5 to raise awareness of promoting employment for persons with disabilities in Kettering, Ohio.
Sign-up for Synchrony Financial’s People with Disabilities Network Hosts Community Event investment picks
http://media.marketwire.com/attachments/201202/21296_SURGLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164288&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics Acquires U.K.-Based Manufacturer Sterimedix Ltd. investment picks
http://media.marketwire.com/attachments/201202/21296_SURGLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164285&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics Reports First Quarter of Fiscal Year 2015 Results investment picks
http://media.marketwire.com/attachments/201202/21296_SURGLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1151453&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics Reports Fourth Quarter and Fiscal Year 2014 Results investment picks
http://media.marketwire.com/attachments/201202/21296_SURGLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162375&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics USA Announces Conference Call to Review First Quarter of Fiscal Year 2015 Results investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from a phase 2 trial assessing safety, efficacy and dose-response of three different once-daily oral SP-333 tablets (1.0, 3.0 and 6.0 mg) compared with placebo in 289 patients with opioid-induced constipation (OIC). Preliminary analysis of the data indicates SP-333 met the study’s primary endpoint and demonstrated statistically significant improvement in mean change from baseline in the number of spontaneous bowel movements (SBMs) during Week 4 of the treatment period.
Sign-up for Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 in connection with its previously announced $175 million Convertible Senior Note offering, bringing total gross proceeds from the offering to $200 million (before deducting the initial purchasers’ discount and other offering expenses payable by the Company). The offering (including the over-allotment option) is expected to close on or about November 3, 2014, subject to customary closing conditions.
Sign-up for Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 (including the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019). The notes are unsecured, senior obligations of Synergy and bear interest at a rate of 7.50% per year, payable semiannually in arrears on May 1 and November 1 of each year, beginning on May 1, 2015.
Sign-up for Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50% Convertible Senior Notes investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019.
Sign-up for Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 Million of 7.50% Convertible Senior Notes investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (the “Company”), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal amount of its convertible senior notes due 2019 (the “notes”) through a private offering.
Sign-up for Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior Notes investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 adult patients (mITT population= 423) with irritable bowel syndrome with constipation (IBS-C). Data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement (CSBM) frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period.
Sign-up for Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC). The trial is currently being conducted at 180 sites and has randomized over 675 CIC patients.
Sign-up for Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), today reported its financial results and business update for the three and nine months ended September 30, 2014.
Sign-up for Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it will present additional positive data from a phase 2b study assessing plecanatide’s efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). The data will be presented during a plenary session at the American College of Gastroenterology’s 2014 Annual Scientific Meeting in Philadelphia, Pennsylvania on October 20, 2014.
Sign-up for Synergy Pharmaceuticals to Present Additional Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation at ACG 2014 Annual Scientific Meeting investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr.
Sign-up for Synergy Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference investment picks
IBM Among Top 3 Cloud Providers ARMONK, N.Y. , Nov.
Sign-up for Synergy Research Ranks IBM as the #1 Hybrid Cloud Provider for the Enterprise investment picks
New Device Featured at the European Academy of Dermatology and Venereology* WAYLAND, Massachusetts , October 8, 2014 /PRNewswire/ -- Syneron Medical Ltd.
Sign-up for Syneron Announces Launch of PicoWay Picosecond Device for Pigmented Lesion Treatment and Tattoo Removal investment picks
The Dual Wavelength PicoWay® Laser will be launched immediately in the US and featured at The American Society of Dermatologic Surgery Meeting, San Diego, November 6-9 WAYLAND, Mass.
Sign-up for Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removal investment picks
2014/11/17
FDA cleared U-Sculpt compact transducer is optimized for treatment of fat pockets of any shape and size.
Sign-up for Syneron Candela Expands Capabilities of UltraShape Non-Invasive Fat Destruction Platform, Receives FDA Clearance for the New U-Sculpt Transducer and Enhanced Ultrasound Power investment picks
FDA Clearance for NS3000, a 30 Watt Holmium Laser for the Urology Market ROSEVILLE, Calif.
Sign-up for Syneron Candela Signs Agreement with American Medical Systems to Supply Holmium Laser for Urology investment picks
YOKNEAM, Israel , Dec.
Sign-up for Syneron Medical Announces $20 Million Share Repurchase Program investment picks
YOKNEAM, Israel , Nov.
Sign-up for Syneron Medical to Participate in Three Investor Conferences in November investment picks
YOKNEAM, Israel , Oct.
Sign-up for Syneron Medical to Report Third Quarter 2014 Financial Results on November 12, 2014 investment picks
Total revenue of $60.3 million; North America revenue grew 16.3% y/y Generated $4.9 million in cash from operations Received FDA clearance for PicoWay; immediate U.S. launch in November 2014 UltraShape U.S. full commercial launch underway YOKNEAM, Israel , Nov.
Sign-up for Syneron Reports Third Quarter 2014 Results investment picks
2014/12/12
By Jacob Bunge Syngenta AG expects China soon will approve imports of a controversial strain of biotech corn that has sparked lawsuits from grain traders and farmers blaming the seed maker for losses because of shipments rejected by Beijing.
Sign-up for Syngenta Expects Chinese Approval for Viptera Corn In Near Future investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Synchrony Financial Reports Third Quarter Net Earnings of $548 Million or $0.70 Per Diluted Share to Syngenta Expects Chinese Approval for Viptera Corn In Near Future
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent